LEO Pharma recently announced that the U.S. Food and Drug Administration (FDA) has approved its new Adbry® (tralokinumab-ldrm) 300 mg single-dose autoinjector for adult patients.
Adbry, which is a high-affinity fully human monoclonal antibody, is currently indicated in the U.S. for the treatment of moderate-to-severe atopic dermatitis in patients 12 years and older.
In their recent press release, LEO Pharma stated that this new single-dose autoinjector will provide adult patients with an alternative method of administration for Adbry in addition to a pre-filled syringe which is already available. This 2mL autoinjector will give adult patients the option to halve the number of injections as the prior pre-filled syringe is a 1mL dose. However, those patients that prefer the pre-filled syringe will continue to have this option available to them in the U.S.
“We are constantly looking for new ways to advance the standard of care and improve the patient experience for our treatment options,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma. “Through this latest approval, a new mode of administration has been made available to provide a more convenient option to support self-administration. Our team will now undertake the necessary steps to ensure patients living across the United States have access to this device in the coming months.”
